Skip to content

Ketamine: all studies

Page 260 of 448: studies 2,591 to 2,600 of 4,475, newest first. Back to the ketamine overview

Research

Decreased Blood Levels of Oxytocin in Ketamine-Dependent Patients During Early Abstinence.

Frontiers in Psychiatry 2018 Ming-Chyi Huang, Lian-Yu Chen, Hu-Ming Chang et al.

Background: Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is a common drug of abuse worldwide. Existing evidence suggest a disruption of oxytocin system involves in the development of addiction. In this study, we aimed to investigate the role of oxytocin in ketamine addiction by measuring the blood oxytocin levels in ketamine-dependent (KD) patients. Methods: Sixty-five KD...

The influence of subanaesthetic ketamine on regional cerebral blood flow in healthy dogs measured with 99mTc-HMPAO SPECT.

PLoS One 2018 Lise Vlerick, Kathelijne Peremans, Robrecht Dockx et al.

Subanaesthetic ketamine has recently been proven to be a highly effective and fast acting alternative treatment for several psychiatric disorders. The mechanisms responsible for ketamine's antidepressant effects remain unclear, but a possible explanation could be that ketamine interacts with regional cerebral blood flow (rCBF). Therefore, the effects of two subanaesthetic ketamine doses on rCBF...

Is the History Repeated? Can (2R,6R)-Hydroxynorketamine be Another Antidepressant?

Journal of experimental neuroscience 2018 Shigeyuki Chaki, Jun-Ichi Yamaguchi

Historically, identification of active metabolites has contributed to drug discovery for psychiatric disorders. It has led to the identification of new medications such as desipramine (a metabolite of imipramine) and paliperidone (a metabolite of risperidone). (R,S)-Ketamine, which has been regarded as the greatest breakthrough in depression research, is rapidly and stereoselectively...

Potential Mechanisms for the Ketamine-Induced Reduction of P3b Amplitudes.

Frontiers in Behavioral Neuroscience 2018 Timm Rosburg, André Schmidt

In specific dosages, the N-methyl-D-aspartate receptor (NMDA) antagonist ketamine can be used to model transient psychotic symptoms in healthy individuals that resemble those of schizophrenia. Ketamine administration also temporarily impairs cognitive functions, which can be studied by event-related potentials (ERPs). ERPs also allow dissecting what stages of information processing are affected...

DOI: 10.3389/fnbeh.2018.00308 (opens in new tab) Full text (opens in new tab) Ketamine N-methyl-d-aspartate Schizophrenia Event-related potentials +3

Decoding Depression: Insights from Glial and Ketamine Regulation of Neuronal Burst Firing in Lateral Habenula.

Cold Spring Harbor Symposia on Quantitative Biology 2018 Yihui Cui, Yan Yang, Yiyan Dong et al. preprint

The rapid antidepressant effect of ketamine is arguably one of the most significant advances in the mental health field in the last half century. However, its mechanism of action has remained elusive. Here, we describe our latest discovery on how ketamine blocks N-methyl-D-aspartate receptor (NMDAR)-dependent burst firing of an "antireward" center in the brain, the lateral habenula (LHb), to...

Both Ketamine and NBQX Attenuate Alcohol-Withdrawal Induced Depression in Male Rats

Journal of Drug and Alcohol Research 2018 Bruk Getachew, Yousef Tizabi 17 citations

The co-morbidity between heavy drinking and depression can negatively influence successful cessation of alcohol use. Since ketamine, a glutamatergic NMDA receptor antagonist, has shown promise as a quick-acting antidepressant, we studied its effects specifically on alcohol withdrawal-induced depression. We also evaluated the effects of NBQX an AMPA/kainate receptor antagonist, because some of...

1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances.

Handbook of experimental pharmacology 2018 Jason Wallach, Simon D. Brandt

While phencyclidine (PCP) and ketamine remain the most well-studied and widely known dissociative drugs, a number of other agents have appeared since the late 1950s and early 1960s, when the pharmacological potential of this class was first realized. For example, hundreds of compounds have been pursued as part of legitimate research efforts to explore these agents. Some of these found their way...

DOI: 10.1007/164_2018_148 (opens in new tab) Full text (opens in new tab) Designer drugs Diphenidine, ketamine analogs Dissociatives Forensic +3

Mechanistic Target of Rapamycin-Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model.

Biological Psychiatry 2018 Chun Yang, Q. Ren, Y. Qu et al. 249 citations

BACKGROUND The role of the mechanistic target of rapamycin (mTOR) signaling in the antidepressant effects of ketamine is controversial. In addition to mTOR, extracellular signal-regulated kinase (ERK) is a key signaling molecule in prominent pathways that regulate protein synthesis. (R)-Ketamine has a greater potency and longer-lasting antidepressant effects than (S)-ketamine. Here we...

Side-effects associated with ketamine use in depression: a systematic review.

The Lancet Psychiatry 2018 Brooke L Short, J. Fong, Verònica Gálvez et al. 551 citations

This is the first systematic review of the safety of ketamine in the treatment of depression after single and repeated doses. We searched MEDLINE, PubMed, PsycINFO, and Cochrane Databases and identified 288 articles, 60 of which met the inclusion criteria. After acute dosing, psychiatric, psychotomimetic, cardiovascular, neurological, and other side-effects were more frequently reported after...